Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
Cell & Bioscience volume 13, Article number: 121 (2023)
BRAFV600E comes as two main splicing variants. The well-studied ref isoform and the recently discovered X1 isoform are co-expressed in cancer cells and differ in terms of 3’UTR length and sequence, as well as C-term protein sequence. Here, we use a melanoma model in zebrafish to study the role played by each isoform in larval pigmentation, nevi formation, and their progression into melanoma tumours. We show that both BRAFV600E-ref and BRAFV600E-X1 proteins promote larval pigmentation and nevi formation, while melanoma-free survival curves performed in adult fish indicate that BRAFV600E-ref protein is a much stronger melanoma driver that BRAFV600E-X1 protein. Crucially, we also show that the presence of the 3’UTR suppresses the effect of ref protein. Our data highlight the necessity to undertake a systematic study of BRAFV600E isoforms, in order to uncover the full spectrum of their kinase-(in)dependent and coding-(in)dependent functions, hence to develop more informed strategies for therapeutic targeting.
Melanoma originates from melanocytes and is responsible for the highest mortality among skin cancers. As a result, significant research has been dedicated to its study, and zebrafish models recapitulating the most common genetic alterations have offered several notable contributions to this field .
A specific characteristic of melanoma is the recurrent overactivation of the ERK pathway, most often because of the BRAFV600E mutation, which is now routinely targeted by specific inhibitors approved for use by the FDA . The BRAF gene is characterised by several splicing variants, and while some of them associated with drug resistance have been well investigated, comparatively little is known about their physiological regulation. Different protein isoforms may exhibit different biological properties, including catalytic capacity, subcellular localization, and protein–protein interaction. Similarly, distinct mRNA isoforms may gain unique binding sites for miRNAs and RNA-binding proteins. In short, investigating the landscape of BRAF isoforms may reveal kinase- and coding-(in)dependent functions that directly or indirectly affect melanoma onset, progression or escape from antineoplastic treatments.
We recently reported that irrespectively of its mutational status human BRAF is expressed as a mix of ref, X1 and X2 splicing variants. The reference (ref) isoform is composed of 18 exons. Exon 18 contains the STOP codon and a short 3’UTR (~ 100nt). The X1 isoform is composed of a shorter version of exon 18, which is spliced with a downstream exon 19. This last exon contains the STOP codon and a very long 3’UTR (~ 7000nt). The X2 isoform lacks exon 18, with exon 17 directly spliced with exon 19. Also in this case, exon 19 contains the STOP codon, through a different frame, and the very long 3’UTR  (see also Additional file 1 : Fig. S1). These isoforms are always co-expressed in cancer cells, with X1 much more expressed than ref and X2 . Interestingly, ref and X1 3’UTRs are subjected to post-transcriptional regulation by distinct groups of microRNAs and RBPs. They positively or negatively affect mRNA stability or translation, and, consequently, contribute to fine tune the output of MAPK signaling pathway [4,5,6]. In terms of proteins, ref and X1 differ at the C-terminal domain (ref: –GYGAFPVH vs. X1: –GYGEFAAFK), are both endowed with kinase activity, and together account for the known oncogenic features displayed by BRAFV600E in melanoma cells [3, 7] (see also Additional file 1 : Fig. S1). Conversely, X2 protein is quite unstable and rapidly undergoes proteasome-dependent degradation, due to the presence of K739 residue in its C-terminal domain .
Here, we use a p53-mutated tumour-prone zebrafish line to compare the BRAFV600E-ref isoform with the BRAFV600E-X1 isoform. We found that BRAFV600E-ref protein is a much stronger melanoma driver than BRAFV600E-X1 protein, but this difference is abolished in presence of the 3’UTR.
Currently, five annotated protein sequences are documented for BRAF and two of them are included in the consensus coding sequence database (CCDS): #220 and #204. Comparing the most updated annotation with our own previous studies , we conclude that the ref isoform corresponds to #220 and the X1 isoform corresponds to #204, while X2 is not currently annotated in the CCDS. Current mRNA sequences are: NM_004333.6 and ENST00000646891.2 for BRAF-ref, NM_001354609.2 and ENST00000496384.7 for BRAF-X1, and NM_001378468.1 for BRAF-X2.
To the best of our knowledge, all in vivo cancer models available so far make use of BRAFV600E-ref cds . In particular, the expression of Myc-tagged BRAFV600E oncogene in the melanocytic lineage of zebrafish leads to the formation of nevi that progress to melanoma in case of p53 deficiency (Tg(mitfa:BRAFV600E-Myc);p53(lf) line ). Building up on this, we have developed a model system that allows to compare BRAFV600E-ref versus X1 cds isoforms, as well as to investigate the contribution of the respective 3’UTRs. Specifically, we generated plasmids expressing ref or X1 cds, with or without their 3’UTR (Fig. 1a, see also Additional files 2, 3, 4). As reported in , we used mitfa promoter to confine the expression of the oncogene in melanocytes. However, we avoided fusing the proteins’ C-terminal domain to a tag, as that would compromise our ability to discriminate their different functionalities. As far as 3’UTRs are concerned, their size was chosen based on our previous analysis: 121nt for ref and 7163nt for X1 . Also, we relied on the expression of a cardiac eGFP reporter to screen for plasmid integration. Finally, plasmid cloning was performed using Tol2kit, so that the DNA portion of the plasmid located between Tol2 elements gets effectively integrated in the zebrafish genome through Tol2-mediated transgenesis.
Plasmids were co-injected with Transposase mRNA in 1-cell embryos of the p53-mutant and tumor-prone ZDB-ALT-050428-2 (p53(lf)) zebrafish line. At 24 h post fertilization (hpf) we selected successfully injected embryos based on the presence of a green heart. We also validated the expression of all BRAFV600E isoforms, including coding sequence (cds)-only and coding sequence plus 3’UTR (cds + 3’UTR) transcripts (Additional file 1 : Fig. S2a, b). mRNA levels were quantified at both 24hpf and 5 days post fertilization (dpf) (Additional file 1 : Fig. S2c, d). Interestingly, we noticed that X1 cds + 3’UTR expression is much higher compared to ref cds + 3’UTR, in agreement with the data we reported on melanoma samples and cell lines .
We thus proceeded to the analysis of the biological consequences of BRAFV600E isoform overexpression. The mosaic condition exhibits altered pigmentation starting at the larval stage (5dpf). This phenotype is most apparent for recipients of the ref and X1 cds plasmids, while cds + 3’UTR recipients display a milder phenotype (Fig. 1b). Such trend is maintained at the juvenile stage, in terms of percentage of animals showing development of a nevus (Fig. 1c, upper, d and Additional file 1 : Fig. S3a), and upon reaching adulthood, in terms of nevi size (Fig. 1c, middle, e, f and Additional file 1 : Fig. S3b). As expected, the X2 variant shows no impact at any stage of development. Reflecting the fact that nevi number and size are important clinical prognostic factors in human, we recorded melanoma-free survival curves at the adult stage over a 1-year observation period, focusing on the comparison between ref and X1. Strikingly, we found that ref cds is a much stronger melanoma driver than all the others (Fig. 1c, lower, g and Additional file 1 : Fig. S4), without affecting the development of tumors across the fish body (Fig. 1h), but potentially enhancing the emergence of melanotic tumors (Fig. 1i).
It remains to be elucidated how the few amino acids distinguishing BRAFV600E-ref and –X1 have no impact on nevi development (compare yellow and green in Fig. 1b, d–f), while they have such a dramatic impact on nevi transformation into melanoma (compare yellow and green lines in Fig. 1g). Major alterations in BRAFV600E protein levels or ability to activate ERK pathway can be excluded (Fig. 1j, k and Additional file 1 : Fig. S5). However, more detailed analyses in ad hoc experimental settings may reveal subtle differences in substrate preferences. Another possibility is that the different C-terminal domains exert kinase-independent functions, such as interactions with different sets of proteins and activation of different signaling pathways, or are engaged in different regulatory mechanisms.
The milder effect exhibited by the cds + 3’UTR plasmids is likely because 3’UTRs are intrinsically devoted to regulation and tuning of gene expression . Nevertheless, several puzzling issues remain: why the short ref 3’UTR mildly affects nevi development (compare yellow and blue in Fig. 1b, d–f), but has a dramatic impact on nevi transformation into melanoma, completely reversing the effect of ref cds (compare yellow and blue lines in Fig. 1g)? Conversely, why the long X1 3’UTR severely delays nevi development (compare green and purple in Fig. 1b, d–f), in spite of the fact that it ensures higher expression levels to X1 cds + 3’UTR mRNA (compare green and purple bars in Additional file 1 : Fig. S2c, d), and then it has a negligible impact on nevi transformation into melanoma (compare green and purple lines in Fig. 1g)? In general terms, we can speculate that the impact of the X1 3’UTR is mild, being the X1 cds a weak melanoma driver per se, while the ref 3’UTR contributes to tame the strong oncogenicity of the ref cds. However, the mechanistic details underlying each biological outcome, in each phase of fish life, remain to be uncovered taking advantage of the more homogeneous genetic background provided by stable transgenic lines.
In summary, in this work we show that different cds and 3’UTR sequences of BRAFV600E differentially affect tumorigenesis in a zebrafish melanoma model. This experimental data urge to undertake a systematic analysis of BRAFV600E isoforms beyond the ref kinase, which so far has catalyzed the attention of the melanoma scientific community. Populating the field of kinase- and coding-(in)dependent functions of BRAFV600E isoforms can in turn prove instrumental to achieve a more informed, hence more effective, therapeutic targeting. Since ref and X1 isoforms are co-expressed across cancer types, our data also suggests generating and testing appropriate constructs in other experimental models of (BRAFV600E-driven) cancer types. Finally, it highlights the necessity to include untranslated regions, as they can heavily modify the biological outcome.
Transcending the boundaries of cancer biology, our findings indicate that BRAF gene has evolved significantly: the older X1 protein is present in the ancient vertebrate lamprey, while the younger ref protein appears in marsupials (wallaby) (Additional file 1 : Fig. S6). Alternative splicing is a key component of biological complexity, and it is gaining momentum for its role in adaptation and evolution . Therefore, we need to understand how and when ref isoform originated. We also need to discover the specific functions it carries out and whether its low levels represent a failsafe mechanism, since it is so oncogenic when mutated.
Availability of data and materials
3’ Untranslated region
Days post fertilization
Food and drug administration
Hours post fertilization
RNA binding protein
Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, et al. Melanoma models for the next generation of therapies. Cancer Cell. 2021;39:610–31.
Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer. 2020;6:797–810.
Marranci A, Jiang Z, Vitiello M, Guzzolino E, Comelli L, Sarti S, et al. The landscape of BRAF transcript and protein variants in human cancer. Mol Cancer. 2017;16:1.
Fattore L, Mancini R, Acunzo M, Romano G, Lagana A, Pisanu ME, et al. miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci USA (Internet). 2016;113:E5005-13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27503895.
Marranci A, D’Aurizio R, Vencken S, Mero S, Guzzolino E, Rizzo M, et al. Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of BRAF-X1 mRNA. RNA Biol. 2019;16:1.
Marranci A, Prantera A, Masotti S, De Paolo R, Baldanzi C, Podda MS, et al. PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation. J Hematol Oncol. 2023;16:33.
Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, et al. Development of a yeast-based system to identify new hBRAFV600E functional interactors. Oncogene. 2019;38:1.
Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (Internet). 2005/02/08. 2005;15:249–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15694309.
Erson-Bensan AE. RNA-biology ruling cancer progression? Focus on 3′UTRs and splicing. Cancer Metastasis Rev. 2020;39:887–901.
Verta J-P, Jacobs A. The role of alternative splicing in adaptation and evolution. Trends Ecol Evol. 2022;37:299–308.
The authors thank M. Lanza, M.S. Podda together with all Poliseno lab members for helpful discussions. Authors also thank E. Guzzolino and A. Marranci for critical reading of the manuscript.
This work was supported by Istituto per lo Studio, la Prevenzione e la Rete Oncologica (institutional funding to LP). It was also partially supported by AIRC-Associazione Italiana Ricerca sul Cancro (MFAG #17095 and IG #25694 to LP).
Ethics approval and consent to participate
Consent for publication
None to declare.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
De Paolo, R., Sarti, S., Bernardi, S. et al. Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma. Cell Biosci 13, 121 (2023). https://doi.org/10.1186/s13578-023-01064-w
- Melanoma modeling